ライフサイエンスコーパス: neonatal sepsis

1 ptibility and improve infectious outcomes in neonatal sepsis.

2 hey are a potential protective agent against neonatal sepsis.

3 e predominantly associated with detection of neonatal sepsis.

4 iotic classes, including those used to treat neonatal sepsis.

5 cribed antibiotics used for the treatment of neonatal sepsis.

6 n is crucial to prevent antibiotic-resistant neonatal sepsis.

7 preventable and among these, 10% are due to neonatal sepsis.

8 agnostic, and prognostic clinical utility in neonatal sepsis.

9 neonates who died from perinatal asphyxia or neonatal sepsis.

10 multiple antibiotic-resistant lineages cause neonatal sepsis.

11 s with very low birth weight from late-onset neonatal sepsis.

12 second-line empiric antibiotic regimens for neonatal sepsis.

13 quisition of S. agalactiae, a major cause of neonatal sepsis.

14 gesting an impaired bactericidal response in neonatal sepsis.

15 mly selected 422 of which 12.8% (n = 54) had neonatal sepsis.

16 ising avenues to prevent and/or treat severe neonatal sepsis.

17 acterial interactions in the early stages of neonatal sepsis.

18 inolyticus may be an underdiagnosed cause of neonatal sepsis.

19 f death and had either perinatal asphyxia or neonatal sepsis.

20 eterm infants are at high risk of developing neonatal sepsis.

21 nts to prevent necrotizing enterocolitis and neonatal sepsis.

22 perbilirubinemia, neonatal hypoglycemia, and neonatal sepsis.

23 ological processes undergo disruption during neonatal sepsis.

24 are non-specific and could be confused with Neonatal sepsis.

25 ciated with the inclusion of only EOS or all neonatal sepsis.

26 ogens when determining antibiotic choice for neonatal sepsis.

27 nes and their relatedness to strains causing neonatal sepsis.

28 owth of pathogens frequently associated with neonatal sepsis.

29 ing efforts designed to reduce the burden of neonatal sepsis.

30 e agent influence the clinical expression of neonatal sepsis.

31 tiae (GBS) is the leading cause worldwide of neonatal sepsis.

32 neumoniae, two pathogens commonly related to neonatal sepsis.

33 specially in the setting of culture-negative neonatal sepsis.

34 nces in the incidence of chorioamnionitis or neonatal sepsis.

35 ality and its mechanism in a murine model of neonatal sepsis.

36 r immune-modulating adjunctive therapies for neonatal sepsis.

37 The primary outcome was the incidence of neonatal sepsis.

38 coccus, the leading pathogens of early-onset neonatal sepsis.

39 neonates can be used to augment survival to neonatal sepsis.

40 is known about the role of MyD88 or TRIF in neonatal sepsis.

41 often shares similar clinical features with neonatal sepsis.

42 c, prognostic and therapeutic strategies for neonatal sepsis.

43 vent a significant proportion of early-onset neonatal sepsis.

44 of their potential to impact mortality from neonatal sepsis.

45 cent literature on novel diagnostic tests in neonatal sepsis.

46 a critical role for CXCL10 signaling during neonatal sepsis.

47 the association between HMOs and late-onset neonatal sepsis.

48 the incidence and mortality associated with neonatal sepsis.

49 noglobulin and colony-stimulating factors in neonatal sepsis.

50 itis and delivered neonates with early-onset neonatal sepsis.

51 sues, and reduced body weight and death from neonatal sepsis.

52 ly reduce both the incidence and severity of neonatal sepsis.

53 s pneumoniae is a rarely recognized cause of neonatal sepsis.

54 r ankle, two had Blount disease, and one had neonatal sepsis.

55 ty contributes to increased mortality during neonatal sepsis.

56 0.8%; RD, 0.04 [95% CI, -0.27 to 0.35]) and neonatal sepsis (1.3% vs 1.3%; RD, 0.02 [95% CI, -0.38 t

57 erinatal asphyxia or hypoxia (98 [22%]), and neonatal sepsis (50 [11%]).

58 t preterm birth complication, 128 (45%) with neonatal sepsis, 69 (24%) with lower respiratory infecti

59 Preterm infants are susceptible to neonatal sepsis, a syndrome of pro-inflammatory activity

60 Finally, in the cecal slurry model of neonatal sepsis, A1ATM383S-CF improved survival in C57BL

61 find prevalence and factors associated with neonatal sepsis among neonates admitted in Kibungo Refer

62 and the presence of ARGs was a predictor of neonatal sepsis and adverse birth outcomes.

63 etermine the incidence and associations with neonatal sepsis and all-cause mortality in facility-born

64 Additionally, it is a leading cause of neonatal sepsis and childhood mortality across the globe

65 tant (AMR) healthcare-associated infections, neonatal sepsis and community-acquired liver abscess, an

66 reterm delivery, and the neonate is prone to neonatal sepsis and death.

67 reduced IL-18-potentiated mortality to both neonatal sepsis and endotoxemia.

68 val rates from serious infections, including neonatal sepsis and health-care-associated infections, a

69 eading pathogen globally underlying cases of neonatal sepsis and is frequently resistant to antibioti

70 lebsiella pneumoniae is the leading cause of neonatal sepsis and is increasingly difficult to treat o

71 Nevertheless, limited information exists on neonatal sepsis and its associated factors in Rwanda.

72 hydrocephalus with and without a history of neonatal sepsis and meningitis (hydrocephalus cohort) fr

73 B Streptococcus (GBS) is a leading cause of neonatal sepsis and meningitis and an important cause of

74 richia coli K1 is the leading cause of human neonatal sepsis and meningitis and is important in other

75 Streptococcus (GBS) is the leading cause of neonatal sepsis and meningitis in developed countries.

76 Streptococcus (GBS) is the foremost cause of neonatal sepsis and meningitis in the United States.

77 Paenibacillus spp causes neonatal sepsis and meningitis in Uganda and is the domi

78 Nevertheless, it can cause severe neonatal sepsis and meningitis often clinically indistin

79 oup B streptococci (GBS), a leading cause of neonatal sepsis and meningitis, are transferred to neona

80 B Streptococcus [GBS]) is a leading cause of neonatal sepsis and meningitis, peripartum infections in

81 Key features of Escherichia coli K1-mediated neonatal sepsis and meningitis, such as a strong age dep

82 up B Streptococcus (GBS) is a major cause of neonatal sepsis and meningitis.

83 nia, and group B Streptococcus, which causes neonatal sepsis and meningitis.

84 ates during childbirth is a leading cause of neonatal sepsis and meningitis.

85 p B Streptococcus (GBS) is a common cause of neonatal sepsis and meningitis.

86 tococcus (GBS) is the leading cause of human neonatal sepsis and meningitis.

87 B streptococci (GBS) are a leading cause of neonatal sepsis and meningitis.

88 New interventions are needed to decrease neonatal sepsis and mortality in regions with highest bu

89 maternal infections but showed no effect on neonatal sepsis and mortality.

90 ed coverage of antibiotics for pneumonia and neonatal sepsis and of oral rehydration solution for dia

91 used to investigate factors associated with neonatal sepsis and parametric survival models for facto

92 is 89% and 83% for cut-offs of 10ng/mL (for neonatal sepsis and pelvic inflammatory disease) and 30n

93 ination on cases and deaths of K. pneumoniae neonatal sepsis and project the global effects of routin

94 ognized effector of IL-18-mediated injury in neonatal sepsis and that disruption of the deleterious a

95 model, we used data from 3 global studies of neonatal sepsis and/or mortality-with 2,330 neonates who

96 dhood illnesses (eg, pneumonia, malaria, and neonatal sepsis) and delivery of preventive intervention

97 om perinatal asphyxia, 562 (47.0%) died from neonatal sepsis, and 156 (13.1%) from both conditions.

98 cus (GBS), is associated with preterm birth, neonatal sepsis, and stillbirth.

99 bstantial proportion of neonates who develop neonatal sepsis, and the high mortality rates among neon

100 s (GBS) results in 12,000 to 15,000 cases of neonatal sepsis annually in the United States.

101 Among cases with neonatal sepsis, antibiotics were administered to 86.8%

102 Improved diagnostics for neonatal sepsis are urgently needed.

103 is one of the most common organisms causing neonatal sepsis as well as serious infections in adults.

104 ated to identify the factors associated with neonatal sepsis at 95% CI, p < 0.05.

105 and South Asia, with perinatal asphyxia and neonatal sepsis being the leading causes of neonatal mor

106 erials have emerged as a better platform for neonatal sepsis biomarkers detection.

107 oxygen therapy, the presence of concomitant neonatal sepsis, BPD, IVH, PDA, and NEC further increase

108 Precise estimates of neonatal sepsis burden vary by setting.

109 or to chorioamnionitis, fetal infection, and neonatal sepsis, but the understanding of specific facto

110 tes an inflammatory cytokine response during neonatal sepsis by directly compromising control of bact

111 Within these studies, 26.95% of fatal neonatal sepsis cases were culture-positive for K. pneum

112 deaths and 399,015 [CrI: 334,523 to 485,442] neonatal sepsis cases yearly worldwide, accounting for m

113 Neonatal sepsis caused ~400 000 deaths globally in 2015,

114 In the DRC, neonatal sepsis causes 15.6% of this mortality, but data

115 Antibiotic regimens used in neonatal sepsis commonly diverge from WHO guidelines, an

116 ncreasing evidence suggests that exposure to neonatal sepsis contributes to ROP development.

117 siders country-level trends in K. pneumoniae neonatal sepsis deaths and is unable to consider within-

118 n credible interval (CrI): 5.24 to 41.42] of neonatal sepsis deaths are caused by meropenem-resistant

119 cs of women with preterm IAI and the risk of neonatal sepsis deserve further study.

120 neonates who died from perinatal asphyxia or neonatal sepsis determined by postmortem diagnostics.

121 Early-onset neonatal sepsis due to Streptococcus agalactiae (group B

122 Although neonatal sepsis due to the peripartum transmission of S.

123 tra-amniotic infection (IAI) and early-onset neonatal sepsis (EONS).

124 neonatal infections in additional to regular neonatal sepsis evaluations.

125 ints, transcriptional interrogation of human neonatal sepsis finds upregulation of many genes involve

126 se and burden of antimicrobial resistance in neonatal sepsis for seven LMICs in Africa and South Asia

127 and pathways of transmission for early-onset neonatal sepsis globally.

128 Biomarkers in human neonatal sepsis have been repeatedly identified as assoc

129 ctoferrin in the prevention and treatment of neonatal sepsis have been reviewed.

130 adjuvant for the prevention and treatment of neonatal sepsis holds promise.

131 antibiotic combinations for the treatment of neonatal sepsis in areas with high rates of multidrug-re

132 B Streptococcus (GBS) is a leading cause of neonatal sepsis in developed countries.

133 findings suggest that a large proportion of neonatal sepsis in developing countries could be effecti

134 reptococcus (GBS) remains a leading cause of neonatal sepsis in high-income contexts, despite decline

135 ic profiles of commonly isolated GNB causing neonatal sepsis in LMICs.

136 erpin research towards better treatments for neonatal sepsis in LMICs.

137 negative bacteria (GNB) are a major cause of neonatal sepsis in low- and middle-income countries (LMI

138 ion could reduce the burden of K. pneumoniae neonatal sepsis in low- and middle-income countries (LMI

139 egative (GN) pathogens are a common cause of neonatal sepsis in low- and middle-income countries.

140 is found to be identical to isolates causing neonatal sepsis in Pakistan over similar time periods.

141 fatality, and underlying comorbidities, and neonatal sepsis incidence and case fatality within the n

142 w of technologies for the rapid diagnosis of neonatal sepsis includes new adaptations of time-honored

143 to identify major biomarkers associated with neonatal sepsis including Serum Amyloid A (SAA), C - rea

144 Considering the fact that the incidence of neonatal sepsis increases dramatically with decreasing g

145 t to that of the maternal tetanus vaccine on neonatal sepsis infections and mortality.

146 for the development of biosensors detecting neonatal sepsis infections.

147 deaths across the world are occurred due to neonatal sepsis infections.

148 e slowest progress were congenital, preterm, neonatal sepsis, injury, and other causes.

149 omes (perinatal death, chronic lung disease, neonatal sepsis, intraventricular hemorrhage >grade 2, p

150 Neonatal sepsis is a bloodstream infection primarily cau

151 Neonatal sepsis is a leading cause of neonatal mortality

152 Neonatal sepsis is a major cause of childhood mortality.

153 Neonatal sepsis is a primary cause of neonatal mortality

154 Neonatal sepsis is a significant cause of morbidity and

155 tment with a Toll-like receptor 4 agonist to neonatal sepsis is dependent on an endogenous CXCL10 res

156 re efficient and effective identification of neonatal sepsis is needed to target interventions to red

157 Neonatal Sepsis is referred as a critical response to th

158 Antimicrobial resistance in neonatal sepsis is rising, yet mechanisms of resistance

159 In Bangladesh, neonatal sepsis is the cause of 24% of neonatal deaths,

160 Neonatal sepsis is the cause of substantial morbidity an

161 Fear of missing evolving neonatal sepsis is the key driver for antibiotic overtre

162 ility and clinical data for 916 out of 1,038 neonatal sepsis isolates (97 isolates were not recovered

163 antial progress has been achieved concerning neonatal sepsis, its lethality remains considerably high

164 de range of other acute illnesses, including neonatal sepsis-like disease, acute flaccid paralysis, a

165 encephalitis, acute respiratory illness, and neonatal sepsis-like disease.

166 up B Streptococcus (GBS) is a major cause of neonatal sepsis, meningitis in early infancy, postpartum

167 e whether Paenibacillus spp is a pathogen in neonatal sepsis, meningitis, and postinfectious hydrocep

168 sistant A. baumannii lineage associated with neonatal sepsis mortality in Asia.

169 agonists may be a useful strategy to prevent neonatal sepsis mortality.

170 n in neonatal respiratory distress syndrome, neonatal sepsis, necrotising enterocolitis, and admissio

171 Neonatal sepsis occurred in 23 (2%) of 923 neonates whos

172 Neonatal sepsis occurred in 9.8% and 9.6% of the infants

173 e 17.7% of very low birth weight infants had neonatal sepsis, only 2.1% of low birth weight and 0.6%

174 veillance hospitals with physician-diagnosed neonatal sepsis or ALRTI were enrolled.

175 er, S. bovis is capable of causing fulminant neonatal sepsis or meningitis that is indistinguishable

176 are few published data on the acute costs of neonatal sepsis or meningitis, with none in SSA.

177 The primary outcome was a composite of neonatal sepsis or mortality, with the former defined ba

178 inistered orally during labor did not reduce neonatal sepsis or mortality.

179 ur with the intension of assessing effect on neonatal sepsis or mortality.

180 bor, intraamniotic or postpartum infections, neonatal sepsis, or admission of the infant to the neona

181 ect C-reactive protein (CRP)-a biomarker for neonatal sepsis, pelvic inflammatory disease, and inflam

182 es of 150 neonates with possible early-onset neonatal sepsis (pEOS) were obtained at the Hopital Prov

183 most significant bacterial pathogen causing neonatal sepsis, pneumonia and meningitis in the USA des

184 most significant bacterial pathogen causing neonatal sepsis, pneumonia, and meningitis in the United

185 eptococci (GBS) are the most common cause of neonatal sepsis, pneumonia, and meningitis.

186 n might be a crucial tolerance mechanism for neonatal sepsis preserving neural control of breathing.

187 Neonatal sepsis remains one of the leading causes of mor

188 Successful management of neonatal sepsis requires early diagnosis, appropriate an

189 ectrum antibiotics for suspected early-onset neonatal sepsis (sEONS) may have pronounced effects on g

190 lk samples from the mother of an infant with neonatal sepsis; sequencing of the enterovirus isolate i

191 l as other extracellular bacterial agents of neonatal sepsis (staphylococci and enterococci) induced

192 ery preterm and 89 (88-91) for children with neonatal sepsis, thus showing clinical validity.

193 lop a severity score predicting mortality in neonatal sepsis to inform future clinical trial design.

194 common causes such as maternal hypertension, neonatal sepsis, twin-twin transfusion, alloimmunization

195 In neonates, the incidence of neonatal sepsis was 1,006 cases per 100,000 live births.

196 In this nationwide cohort study, early-onset neonatal sepsis was associated with an approximately 2-f

197 Surveillance for suspected neonatal sepsis was conducted in Mirzapur, Bangladesh, f

198 Neonatal sepsis was strongly associated with neonatal ag

199 Using a preterm pig model of neonatal sepsis, we previously showed that a drastic res

200 an the normative mean, and for children with neonatal sepsis were 0.73 SD lower on average than the n

201 use in lower respiratory tract infection and neonatal sepsis were observed between WHO regions and co

202 entified HLA-DRhiCD83+ gammadelta T cells in neonatal sepsis, which expressed genes related to antige

203 the most common immediate cause of death was neonatal sepsis, which occurred in 27 (60%).

204 ms were the predominant cause of early-onset neonatal sepsis, with a high prevalence of extended-spec

205 a pneumoniae (n = 258) was the main cause of neonatal sepsis, with Serratia marcescens (n = 151), Kle